ClinicalTrials.gg
Not yet recruitingNCT07262034Updated Mar 6, 2026

The Impact of Preoperative Nutrition Intervention on Muscle Mass Preserve in Older Adults Undergoing Elective Surgery

An observational study in Nutrition Status, sponsored by Siriraj Hospital. Not yet recruiting at 1 site in Thailand. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Siriraj Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Sarcopenia with a site in Thailand — 6 open to participants now, 6 under way, 1 of them phase 3. Sarcopenia · Thailand.

Started
2026
with 1 other
Observational
4 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
3 of 12
Siriraj Hospital

Among the 12 studies in Sarcopenia with a site in Thailand, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 11th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

6 of the 12 studies in Sarcopenia with a site in Thailand are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Sarcopenia with a site in Thailand, or all of them as a file.
02

Study summary

Sarcopenia-the progressive loss of muscle mass and strength-is a major clinical issue, especially in surgical patients with malignancy. It's strongly linked to poor postoperative outcomes like increased complications, longer hospital stays, and higher mortality. Surgical stress (trauma, fasting, immobilization) significantly worsens this muscle catabolism.

Consequently, early identification and targeted preoperative intervention are essential. Preoperative nutrition, part of a prehabilitation program, is a key strategy known to attenuate muscle loss and improve recovery. The Skeletal Muscle Index (SMI) is an objective metric used for risk stratification.

The Siriraj Integrated Preoperative and Prehabilitation Center (SiPAP) uses a multidisciplinary model with nutritional counseling, but lacks routine sarcopenia screening or objective SMI measurement. Therefore, the impact of their specific nutritional interventions on preserving muscle mass remains unevaluated.

Hypothesis: The structured, individualized preoperative nutritional intervention delivered by SiPAP to intraabdominal oncology patients will result in a net preservation or positive change in the Skeletal Muscle Index (SMI) over the preoperative period.

Read the detailed description

Sarcopenia, defined as the progressive loss of skeletal muscle mass and strength, is clinically associated with poor clinical outcomes, increased physical disability, and low quality of life.1 Sarcopenia is common in a geriatric population, but it is also frequently observed in patients with cancer and other chronic conditions..

In patients undergoing surgery, especially those with malignancy, sarcopenia is independently associated with poor postoperative outcomes. It leads to frailty, delayed functional recovery, increased complication rates, prolonged hospital stays, and higher mortality.2-9 For cancer patients, a progressive decrease in muscle mass is a common issue, even during treatment such as neoadjuvant chemotherapy.10-12 This catabolic state is clinically relevant even over short time frames. A reduction of ≥10% in skeletal muscle index is considered clinically meaningful, and even modest short-term losses of 5-10% muscle mass in surgical or oncology patients are associated with poorer clinical outcomes and delayed recovery. 4,6,13-15 The pathophysiology of sarcopenia is multifactorial, involving reduced protein intake, physical inactivity, systemic inflammation, and hormonal changes. Surgical stress exacerbates muscle catabolism through mechanisms such as surgical trauma, perioperative fasting, and postoperative immobilization. 3-6,8,16-19 These effects are particularly concerning in older patients undergoing major procedures.3-6,8,16-19 Consequently, early identification and targeted intervention to preserve muscle integrity are essential of perioperative care for improving postoperative recovery and surgical outcomes. Body composition assessment, particularly using the skeletal muscle index (SMI), is an important metric in preoperative risk stratification and may help identify patients most likely benefit from prehabilitation.

Preoperative nutritional interventions, delivered as part of structured prehabilitation program, represent a key strategy to counteract perioperative muscle wasting. These interventions programs typically involve individualized nutrition counseling, targeted protein supplementation, and physical activity guidance. 20-28 Several studies have demonstrated the beneficial effects of optimizing nutrition to prevent and manage sarcopenia. Tailored dietary advice, with particularly focus on adequate protein intake, has been shown to attenuate muscle mass loss and improve muscle strength in patients at- risk patients of or diagnosed with sarcopenia. 22,24,26,27 In older surgical patients, individualized nutrition interventions are associated with improvements in physical performance measures such as gait speed, and handgrip strength, and short physical performance.27 Furthermore, nutritional guidance, when combined with exercise therapy as part of multimodal prehabilitation, has been reported to enhance muscle protein synthesis, support functional recovery, and reduce sarcopenia progression both before and after surgery. 24,28 These findings highlight the critical role of structured nutritional counseling in preserving skeletal muscle integrity during the perioperative period, aligning with the principles of Enhanced Recovery After Surgery (ERAS) protocols aimed to optimize patients' physical status and accelerating recovery.29-32 The Siriraj Integrated Preoperative and Prehabilitation Center (SiPAP) implements a multidisciplinary prehabilitation model, including comprehensive nutritional counseling and nutritional status assessments, aligned with ERAS principles. However, SiPAP has never formally screened for sarcopenia, nor has it routinely used objective measures of muscle mass, such as Skeletal Muscle Index (SMI) calculated from Bioelectrical Impedance Analysis (BIA). Given the strong association between sarcopenia and poor surgical outcomes, this represents a significant gap in our current risk stratification. Therefore, the impact of the specific, structured preoperative nutritional interventions provided by SiPAP on objective muscle mass preservation (SMI) and the incidence of sarcopenia has not been evaluated in this population.

Therefore, investigators hypothesizes that is that the structured, individualized preoperative nutritional intervention in intraabdominal oncology patients will result in a net preservation or positive change in in skeletal muscle index over the pre-operative period (between the initial SiPAP consultation and hospital admission for elective surgery.

This prospective study aims to determine the absolute mean change in skeletal muscle index (SMI), which will be measured using bioelectrical impedance analysis (BIA) for the first time in this participants cohort, following the nutritional intervention period. Secondary objectives include

  1. To quantify the absolute change in body weight (kg) and total calorie and protein intake (kcal/day, g/day) at hospital admission preoperatively.
  2. To assess the improvement in nutritional status, defined by a change in PG-SGA, comparing baseline to pre-admission.
  3. To establish the baseline prevalence and the change in sarcopenia classification based on AWGS criteria.
03

Conditions studied

  • Nutrition Status

Browse trials for

Keywords

  • Preoperative
  • Sarcopenia
  • Body Composition Analyzer (BIA)
  • Skeletal Muscle Index (SMI)
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients who enroll to Enchanced Recovery After Surgery (ERAS) program, Siriraj Hospital and referred to the SiPAP program

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 60 years to 90 years
  2. Schedules for elective major surgery and formally enrollment in the Enhanced Recovery After Surgery (ERAS) program at Siriraj Hospital. (At Siriraj Hospital, patients scheduled for pre-specific elective major surgeries are enrolled into the ERAS program as individual hospital protocols for each ERAS module. All patients are informed about the ERAS program by their surgical team.)
  3. Referred to the SiPAP center for prehabilitation based on established ERAS hospital preoperative protocol.
  4. Able to provide written and willing to undergo all research assessments at both time points.

Exclusion criteria

Exclusion Criteria:

  1. Presence of conditions that interfere with bioelectrical impedance analysis (BIA), including an implanted pacemaker or other non-removable electronic medical devices.
  2. Use of medications or supplements known to acutely or chronically affect muscle mass (e.g. , hormonal therapies) during the study period.
  3. Diagnosed neuromuscular disorders that affect baseline muscle mass and strength
  4. Undergo emergency surgery
  5. A planned interval of less than 14 days between the initial SiPAP visit and hospital admission for surgery.
  6. Alcohol consumption or strenuous exercise within the 12 hours preceding the scheduled BIA measurement.
  7. Incomplete data on muscle mass or nutritional assessment at either time point.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Change from Baseline in the skeletal muscle index (SMI) at a day admit to surgery

    Skeletal muscle index (SMI) determined by bioelectrical impedance analysis (BIA) and report as a value with units of kilograms per meter squared (kg/m2)

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

Secondary outcomes

  1. Change from Baseline in nutrition status at a day admit to surgery

    Nutrition status defined by Patient-Generated Subjective Global Assessment (PG-SGA). The minimum PG-SGA score is 0, while the maximum score is 30. The higher the score, the greater the risk of malnutrition.

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

  2. Change from Baseline in sarcopenia classification at a day admit to surgery

    Sarcopenia classification based on the Asian Working Group for Sarcopenia (AWGS) 2019 criteria (Possible Sarcopenia, Sarcopenia, Severe Sarcopenia)

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

  3. Change from Baseline in the body weight at a day admit to surgery

    Body weight report as units of kilograms (kg)

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

  4. Change from Baseline in the total calorie intake at a day admit to surgery

    Total calorie intake report as units of kcal/day

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

  5. Change from Baseline in the total protein intake at a day admit to surgery

    Total protein intake report as units of g/day

    Time frame: From a preoperative clinic consultation (baseline) to a day admit to surgery, up to 3 months

07

Study locations

1 site
  • Siriraj Integrated Preoperative And Prehabilitation Center : SiPAP
    Bangkok Noi, Bangkok 10700, Thailand
08

References and documents

Publications

  • Chaiwat O, Wongyingsinn M, Muangpaisan W, Chalermsri C, Siriussawakul A, Pramyothin P, Thitisakulchai P, Limpawattana P, Thanakiattiwibun C. A simpler screening tool for sarcopenia in surgical patients. PLoS One. 2021 Sep 23;16(9):e0257672. doi: 10.1371/journal.pone.0257672. eCollection 2021. PubMed 34555077 ↗
  • Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4. PubMed 32033882 ↗
  • Nitichai N, Angkatavanich J, Somlaw N, Voravud N, Lertbutsayanukul C. Validation of the Scored Patient-Generated Subjective Global Assessment (PG-SGA) in Thai Setting and Association with Nutritional Parameters in Cancer Patients. Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1249-1255. doi: 10.31557/APJCP.2019.20.4.1249. PubMed 31030501 ↗
  • Taylor BE, McClave SA, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society of Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Crit Care Med. 2016 Feb;44(2):390-438. doi: 10.1097/CCM.0000000000001525. No abstract available. PubMed 26771786 ↗
  • Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017 Mar 1;152(3):292-298. doi: 10.1001/jamasurg.2016.4952. PubMed 28097305 ↗
  • Li C, Carli F, Lee L, Charlebois P, Stein B, Liberman AS, Kaneva P, Augustin B, Wongyingsinn M, Gamsa A, Kim DJ, Vassiliou MC, Feldman LS. Impact of a trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study. Surg Endosc. 2013 Apr;27(4):1072-82. doi: 10.1007/s00464-012-2560-5. Epub 2012 Oct 9. PubMed 23052535 ↗
  • Arribas L, Sabate-Llobera A, Domingo MC, Taberna M, Sospedra M, Martin L, Gonzalez-Tampan AR, Pallares N, Mesia R, Baracos VE. Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards. Clin Nutr. 2022 May;41(5):1059-1065. doi: 10.1016/j.clnu.2022.03.016. Epub 2022 Mar 11. PubMed 35395556 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 20 months is below that.

Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2025
First posted
Dec 3, 2025
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 1, 2028
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07262034
Lead sponsor
Siriraj Hospital
Responsible party
Mingkwan Wongyingsinn, MD (Associate Professor, Siriraj Hospital) — Principal investigator
First posted
Dec 3, 2025
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Mar 6, 2026

Study contacts

Mingkwan Wongyingsinn, MD
Contact
Mingkwan.won@mahidol.ac.th
0819153320
Parujee Nakjuy, BSc
Contact
Parujee.nak@mahidol.ac.th
0822361415 ext. 024199154
Assoc. Prof. Mingkwan Wongyingsinn, MD
study director · Department Of Anesthesiology, Faculty Of Medicine Siriraj Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion